Greater Manchester Medicines Management Group

images courtesy of NHS Photo Library

NHS logo


<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during February 2020

February 2020


Pathways and Guidelines Development Subgroup (PaGDSG)


Following GM-wide consultation and approval by PaGDSG, a new shared care protocol has been published: Penicillamine for the treatment of rheumatoid arthritis or Wilson’s disease in adults.  Development of this SCP had been requested by FMESG to support existing prescribing of penicillamine for these indications.



Draft GMMMG Guidance for the Covert Administration of Medicines in Care Home Settings has been opened for consultation (consultation no. 81).

  • This guidance has been developed by the GM Covert Medicines Task and Finish Group as directed by the GM Safeguarding collaborative. It will form part of a larger GM policy on Principles of Safe Medicine Administration in Care Settings.
  • The guidance is intended to be used by staff in all care homes across GM to provide a consistent approach across the GM footprint.
  • It will avoid duplication of effort when a resident moves homes across a CCG boundary.
    There are no anticipated changes in commissioning or financial implications as a result of this guidance.


Updated GMMMG Dental Antimicrobial Guidelines have now been published.  These have been expanded to provide greater advice on the management of common dental presenting conditions and are aligned with self-care advice from NHSE and GMMMG.

Formulary and Managed Entry Subgroup (FMESG)


On behalf of the GMMMG Formulary and Managed Entry Subgroup prescribing information for primary care: colchicine for pericarditis pain has been developed. 


The following FMESG actions for January 2020 have been proposed. We now seek comments on these proposals.  This consultation is open until 5pm on Monday 30th March.

High Cost Drugs Subgroups


Following GM-wide consultation and approval by GMMMG, an updated High Cost Drugs Pathway for Psoriasis has been published. Key changes include inclusion of certolizumab pegol, guselkumab, tildrakizumab and risankizumab, and positioning of biosimilar adalimumab as the first line option. An outcomes and monitoring framework has been published alongside the pathway.

<< Back



RSS Feed